<DOC>
	<DOCNO>NCT02276300</DOCNO>
	<brief_summary>Investigation peptide vaccination target HER2/neu patient metastasize breast gastric cancer moderate HER2/neu expression .</brief_summary>
	<brief_title>HER2-Peptide Vaccination Patients With Solid Tumors</brief_title>
	<detailed_description>This interventional phase I clinical study investigate safety , tolerability efficacy HER2-derived peptide vaccination . HLA-A2+ patient stage IV metastasize breast gastric cancer HER2 expression ( IHC Score 2+ ) without gene amplification prove FISH analysis , document stable disease objective response least first line systemic chemotherapy/radiotherapy advance disease treat underlying malignant disease 4 week chemo- , radio- immunotherapy include study . The aim study show safety tolerability immunotherapeutic approach investigate efficacy immunotherapy .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Imiquimod</mesh_term>
	<criteria>Patients stage IV metastasize breast gastric cancer document stable disease objective response least first line chemo/ radiotherapy advance disease HER2 IHC score 2+ tumor cell , negative FISH result HLAA2 expression Female male patient age &gt; = 18 year Measurable disease accord RECIST criterion ECOG 01 Neutrophile count &gt; 1,5x10^9/l WBC &gt; 2,5x10^9/l Lymphocyte count &gt; 1x10^9/l Hemoglobin &gt; 10g/dl Platelets &gt; 100x10^9/l Normal renal function ( creatinine &lt; 150 % ULN ) Normal liver function ( Bilirubin &lt; 150 % ULN ; ALAT/SGPT ASAT/SGOT &lt; 300 % ULN , except proven metastasis ) Expected survival least 6 month Concomitant antihormonal treatment allow Female patient within child bearing age must negative pregnancy test perform earlier 21 day administration investigational product . Male female patient reproductive potential must agree employ effective method birth control throughout study 6 month discontinuation investigational product . Postmenopausal woman must amenorrheal least 12 month consider nonchildbearing potential . Men woman childbearing potential must agree use highly effective method birth control result low failure rate ( le 1 % per year ) use consistently correctly . Written informed consent patient legally authorize representative inform aspect study prior enrollment willing participate include study Ability understand comply study followup procedure Treatment investigational drug within 4 week prior start study medication Known hypersensitivity component study product Any severe concomitant disease Any disease ( include psychotic disorder , drug abuse , active infection , uncontrolled hypertension , unstable angina , heart failure , myocardial infarction within previous year , serious cardiac arrhythmia require medication , hepatic , renal metabolic disease , obstructive restrictive lung disease ) metabolic dysfunction ) physical examination find likely ( investigator 's opinion ) affect evaluation study put patient risk associate treatment study medication . Any heart disease Any serious infection sepsis Any autoimmune disorder Infection HIV , chronic infection Hepatitis B C Any immunodeficiency syndrome Surgery within 4 week study entry Prior splenectomy Brain metastasis leptomeningeal involvement Systemic application immunosuppressive drug include systemic corticosteroid within three week study entry Patients eligible treated aproved HER2targeted therapy Trastuzumab , Pertzuzumab , TDM1 Lapatinib Radio , chemo immunotherapy study medication parallel within 4 week prior study start Active drug abuse chronic alcoholism Pregnancy breast feed Female male patient reproductive potential unwilling unable practice highly effective method birth control History noncompliance medical regimen Patients unwilling unable comply protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>